A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.

Thumbnail
View/Open
Publication Date
2018-08
ICR Author
Author
Pratt, G
Yap, C
Oldreive, C
Slade, D
Bishop, R
Griffiths, M
Dyer, MJS
Fegan, C
Oscier, D
Pettitt, A
Matutes, E
Devereux, S
Allsup, D
Bloor, A
Hillmen, P
Follows, G
Rule, S
Moss, P
Stankovic, T
Type
Journal Article
Metadata
Show full item record
URL
https://repository.icr.ac.uk/handle/internal/1518
Collections
Version of record
Subject
Humans
Lymphoma, Mantle-Cell
Lymphoproliferative Disorders
DNA Damage
Recurrence
Piperazines
Phthalazines
Survival Analysis
Maximum Tolerated Dose
Aged
Middle Aged
Female
Male
Tumor Suppressor Protein p53
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Prolymphocytic, T-Cell
Ataxia Telangiectasia Mutated Proteins
Poly(ADP-ribose) Polymerase Inhibitors
Research team
Clinical Trials & Statistics Unit
Language
eng
License start date
2018-08
Citation
British journal of haematology, 2018, 182 (3), pp. 429 - 433